A Multi-center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion.

Trial Profile

A Multi-center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2012

At a glance

  • Drugs Morphine; Naltrexone
  • Indications Pain
  • Focus Therapeutic Use
  • Acronyms ConvERT
  • Sponsors Alpharma
  • Most Recent Events

    • 04 Sep 2012 Actual patient number changed from 679 to 684 as reported by ClinicalTrials.gov record.
    • 22 Sep 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned end date changed from 1 Jan 2012 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top